Targeted therapy of AML
Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
Combining CLL drugs to overcome the problem of resistance
The stratification of CLL patients and implications for clinical practice
How the treatment of ALL is changing